Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2020 May 19;1(2):100016.
doi: 10.1016/j.xcrm.2020.100016. Epub 2020 Apr 30.

Adjunct Immunotherapies for the Management of Severely Ill COVID-19 Patients

Srinivasa Reddy Bonam  1 , Srini V Kaveri  1 , Anavaj Sakuntabhai  2 , Laurent Gilardin  3 , Jagadeesh Bayry  1
Affiliations
Review

Adjunct Immunotherapies for the Management of Severely Ill COVID-19 Patients

Srinivasa Reddy Bonam et al. Cell Rep Med. .

Abstract

Coronavirus disease 2019 (COVID-19) is caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). It has infected millions, with more than 275,000 fatal cases as of May 8, 2020. Currently, there are no specific COVID-19 therapies. Most patients depend on mechanical ventilation. Current COVID-19 data clearly highlight that cytokine storm and activated immune cell migration to the lungs characterize the early immune response to COVID-19 that causes severe lung damage and development of acute respiratory distress syndrome. In view of uncertainty associated with immunosuppressive treatments, such as corticosteroids and their possible secondary effects, including risks of secondary infections, we suggest immunotherapies as an adjunct therapy in severe COVID-19 cases. Such immunotherapies based on inflammatory cytokine neutralization, immunomodulation, and passive viral neutralization not only reduce inflammation, inflammation-associated lung damage, or viral load but could also prevent intensive care unit hospitalization and dependency on mechanical ventilation, both of which are limited resources.

Keywords: COVID-19; IVIG; SARS-CoV-2; convalescent plasma; cytokine storm syndrome; cytokines; hyperimmune globulin; immunotherapy; inflammation; monoclonal antibody; passive immunotherapy.

PubMed Disclaimer

Conflict of interest statement

The authors declare no competing interests.

Figures

None
Graphical abstract
Figure 1
Figure 1
Cytokine Storm in COVID-19 Infection Lungs are the primary organs affected by SARS-CoV-2. A dysregulated cytokine response (i.e., cytokine storm) due to an influx of activated immune cells following SARS-CoV-2 infection results in pulmonary edema, leading to damaged alveoli and formation of scarred interstitium culminating in a reduced gas exchange process. The figure was created with the support of https://biorender.com under the paid subscription.
Figure 2
Figure 2
Immunotherapeutic Strategies for Severely Ill COVID-19 Patients Diversified immunotherapeutic approaches against severe COVID-19 cases are illustrated. The figure was created with the support of https://biorender.com under the paid subscription.
See this image and copyright information in PMC

References

    1. Huang C., Wang Y., Li X., Ren L., Zhao J., Hu Y., Zhang L., Fan G., Xu J., Gu X. Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. Lancet. 2020;395:497–506. - PMC - PubMed
    1. Guan W., Ni Z., Hu Y., Liang W., Ou C., He J., Liu L., Shan H., Lei C., Hui D.S.C., China Medical Treatment Expert Group for Covid-19 Clinical characteristics of coronavirus disease 2019 in China. N. Engl. J. Med. 2020;382:1708–1720. - PMC - PubMed
    1. Zhou P., Yang X.L., Wang X.G., Hu B., Zhang L., Zhang W., Si H.R., Zhu Y., Li B., Huang C.L. A pneumonia outbreak associated with a new coronavirus of probable bat origin. Nature. 2020;579:270–273. - PMC - PubMed
    1. Grasselli G., Zangrillo A., Zanella A., Antonelli M., Cabrini L., Castelli A., Cereda D., Coluccello A., Foti G., Fumagalli R., COVID-19 Lombardy ICU Network Baseline characteristics and outcomes of 1591 patients infected with SARS-CoV-2 admitted to ICUs of the Lombardy Region, Italy. JAMA. 2020;323:1574–1581. - PMC - PubMed
    1. Zhao X., Zhang B., Li P., Ma C., Gu J., Hou P., Guo Z., Wu H., Bai Y. Incidence, clinical characteristics and prognostic factor of patients with COVID-19: a systematic review and meta-analysis. medRxiv. 2020 doi: 10.1101/2020.03.17.20037572. - DOI

Publication types

MeSH terms